Differential expression of receptor activator of nuclear factor-?B ligand and osteoprotegerin mRNA in periodontal diseases

Basit Öğe Kaydı
dc.contributor.authorBostanci N.
dc.contributor.authorIlgenli T.
dc.contributor.authorEmingil G.
dc.contributor.authorAfacan B.
dc.contributor.authorHan B.
dc.contributor.authorTöz H.
dc.contributor.authorBerdeli A.
dc.contributor.authorAtilla G.
dc.contributor.authorMcKay I.J.
dc.contributor.authorHughes F.J.
dc.contributor.authorBelibasakis G.N.
dc.date.accessioned2019-10-27T08:37:24Z
dc.date.available2019-10-27T08:37:24Z
dc.date.issued2007
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground and Objective: Receptor activator of nuclear factor-?B ligand (RANKL) is responsible for the induction of osteoclastogenesis and bone resorption, whereas its decoy receptor, osteoprotegerin, can directly block this action. Because this dyad of cytokines is crucial for regulating the bone remodelling process, imbalances in their expression may cause a switch from the physiological state to enhanced bone resorption or formation. This study investigated the mRNA expression of RANKL and osteoprotegerin, as well as their relative ratio, in the gingival tissues of patients with various forms of periodontal diseases. Material and Methods: Gingival tissue was obtained from nine healthy subjects and 41 patients, who had gingivitis, chronic periodontitis, generalized aggressive periodontitis, and chronic periodontitis and were receiving immunosuppressant therapy. Quantitative real-time polymerase chain reaction was employed to evaluate the mRNA expression of RANKL and osteoprotegerin in these tissues. Results: Compared with healthy individuals, patients in all periodontitis groups, but not those with gingivitis, exhibited stronger RANKL expression and a higher relative RANKL/osteoprotegerin ratio. In addition, osteoprotegerin expression was weaker in patients with chronic periodontitis. When patients with generalized aggressive periodontitis and chronic periodontitis were compared, the former exhibited stronger RANKL expression, whereas the latter exhibited weaker osteoprotegerin expression, and there was no difference in their relative ratio. When chronic periodontitis patients were compared with chronic periodontitis patients receiving immunosuppressant therapy, osteoprotegerin, but not RANKL, expression was stronger in the latter. Conclusion: This study demonstrates that RANKL and osteoprotegerin expression are differentially regulated in various forms of periodontitis, and the relative RANKL/osteoprotegerin ratio appears to be indicative of disease occurrence. This information may confer diagnostic and therapeutic value in periodontitis. © 2007 Blackwell Munksgaard.en_US
dc.identifier.doi10.1111/j.1600-0765.2006.00946.xen_US
dc.identifier.endpage293en_US
dc.identifier.issn0022-3484
dc.identifier.issue4en_US
dc.identifier.pmid17559623en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage287en_US
dc.identifier.urihttps://doi.org/10.1111/j.1600-0765.2006.00946.x
dc.identifier.urihttps://hdl.handle.net/11454/27524
dc.identifier.volume42en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofJournal of Periodontal Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBone resorptionen_US
dc.subjectGingival tissueen_US
dc.subjectOsteoprotegerinen_US
dc.subjectReceptor activator of nuclear factor-?B liganden_US
dc.titleDifferential expression of receptor activator of nuclear factor-?B ligand and osteoprotegerin mRNA in periodontal diseasesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu